Drug Discovery and Drug Design
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 3701
Special Issue Editor
Interests: computational drug repurposing; computational ligand design; machine learning; molecular simulation; transcriptomics data analysis; data mining
Special Issue Information
Dear Colleagues,
The quest for the treatment and prevention of diseases started thousands of years ago, when humans turned to natural extracts to discover new drugs. Drug discovery advanced in the 20th century, when systematic pharmacological evaluations and synthetic organic chemistry came into play. Computer-aided drug design (CADD) emerged in the 1980s, owing to the revolution in molecular biology and information theory, combined with technological advances. Since then, progress made in all related fields of science and technology has fueled drug discovery and design, bringing up new ideas and challenges. Different computational approaches, such as machine learning, network analysis and data mining, make use of heterogeneous data to reveal disease mechanism, to identify new molecular targets with clinical applications, to improve multi-target drug design and to study drug mechanism of action. The chemical space of small molecules expands and biopharmaceuticals are used in practically all branches of medicine. Computational drug repurposing explores new indications of existing drugs, accelerating drug availability and promoting orphan diseases treatment. Last but not least, both bench-to-bedside and bedside-to-bench approaches are used to improve drug development, by translating experimental data to the clinic and converting clinical trial and real‐world data to knowledge.
In this Special Issue, we are inviting papers on various aspects of Drug Discovery and Drug Design, including resources, computational and translational methods, experimental evaluations and applications.
Dr. Trias Thireou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug discovery
- drug design
- translational drug discovery
- reverse translation
- network pharmacology
- drug repurposing
